These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 25956072)

  • 1. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
    Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
    Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
    Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
    Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
    Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C; Ichinose M; Lee SH; Lee KH; Jöns O; Bothner U; Zhao Y; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3329-3339. PubMed ID: 29200840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
    Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
    Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
    Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
    Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
    Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
    Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
    Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.